IDEAS home Printed from https://ideas.repec.org/a/dbk/procee/v3y2025ip1056294piii2025552id1056294piii2025552.html
   My bibliography  Save this article

Cannabidiol: a new effective means for the treatment of patients with refractory epilepsy

Author

Listed:
  • Vitor Nifoci
  • Cristian Emanuel Cabrera

Abstract

Canabidiol (CBD) is one of two main phytocannabinoids extracted from the Cannabis sativa plant, popularly known as marijuana or cannabis, and is characterized by not producing the typical psychoactive effects associated with its recreational use. There is evidence that CBD has neuroprotective, analgesic, anti-inflammatory, antineoplastic, chemopreventive and immunomodulatory properties. Before the legalization of CBD in the United States and Argentina being administered by the government as called REPROCANN (Cannabis Program Registry), it is essential to debate and deepen the knowledge of its use against alternative treatments for epilepsy. Therefore, a detailed investigation into its pharmacological action and its effects in the treatment of epileptic syndromes such as Dravet syndrome and Lennox-Gastaut syndrome is necessary, where there are currently reported cases of success with the use of CBD. Discuss the use of cannabidiol in the treatment of refractory epilepsy. Compare the challenges and effectiveness of treatments involving cannabidiol use with conventional epilepsy treatments. A narrative bibliographic review was carried out using scientific articles published in the last ten years (2014-2024) in Spanish and English. Databases such as Scientific Electronic Library Online (SciELO), Sciencedirect, PubMed and Google Academic were consulted. In addition, resources from national and international institutions, both public and private, were used. Relevant information was also collected from textbooks, websites and other media as necessary for the preparation of this work. For the writing of the final text, only those studies that were aligned with the objectives proposed in this study were selected. In summary, it is suggested that doctors consider prescribing CBD to adults suffering from refractory epilepsy. Despite the lack of sufficient evidence, the inclusion of CBD in conventional treatment could benefit seizure frequency in some patients, with few adverse side effects reported.). Therefore, it is recommended that health professionals consider prescribing CBD for young people and adults with refractory epilepsy, since although there is not enough evidence, its addition to traditional therapy could improve the seizures of some patients with few unwanted reactions.

Suggested Citation

Handle: RePEc:dbk:procee:v:3:y:2025:i::p:1056294piii2025552:id:1056294piii2025552
as

Download full text from publisher

To our knowledge, this item is not available for download. To find whether it is available, there are three options:
1. Check below whether another version of this item is available online.
2. Check on the provider's web page whether it is in fact available.
3. Perform a
for a similarly titled item that would be available.

More about this item

Statistics

Access and download statistics

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:dbk:procee:v:3:y:2025:i::p:1056294piii2025552:id:1056294piii2025552. See general information about how to correct material in RePEc.

If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

We have no bibliographic references for this item. You can help adding them by using this form .

If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Javier Gonzalez-Argote (email available below). General contact details of provider: https://proceedings.ageditor.ar/ .

Please note that corrections may take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.